Elucidating rifampin's inducing and inhibiting effects on glyburide pharmacokinetics and blood glucose in healthy volunteers: Unmasking the differential effects of enzyme induction and transporter inhibition for a drug and its primary metabolite

Clinical Pharmacology and Therapeutics

Volumn 85, Issue 1, 2009, Pages 78-85

  Zheng, H X ^a   Huang, Y ^a   Frassetto, L A ^b   Benet, L Z ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYGLIBENCLAMIDE; CIPROFLOXACIN; DRUG METABOLITE; GLIBENCLAMIDE; GLUCOSE; LIVER ENZYME; RIFAMPICIN; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; DRUG CLEARANCE; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; ENZYME INDUCTION; ENZYME INHIBITION; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; HYPOGLYCEMIA; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NORMAL HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ADULT; ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; BLOOD GLUCOSE; CIPROFLOXACIN; DRUG INTERACTIONS; ENZYME INDUCTION; ENZYME INHIBITORS; FEMALE; GLYBURIDE; HUMANS; HYPOGLYCEMIC AGENTS; INFUSIONS, INTRAVENOUS; LIVER; MALE; METABOLIC CLEARANCE RATE; ORGANIC ANION TRANSPORT POLYPEPTIDE C; RIFAMPIN;

EID: 57749171180     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2008.186     Document Type: Article

References (33)

1. Abe, T. et al. Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J. Biol. Chem. 274, 17159-17163 (1999).
2. König, J., Cui, Y., Nies, A.T. & Keppler, D. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am. J. Physiol. Gastrointest. Liver Physiol. 278, G156-G164 (2000).
3. Konig, J., Cui, Y., Nies, A.T. & Keppler, D. Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J. Biol. Chem. 275, 23161-23168 (2000).
4. Satoh, H. et al. Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B. Drug Metab. Dispos. 33, 518-523 (2005).
5. Wu, C.Y. & Benet, L.Z. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm. Res. 22, 11-23 (2005).
6. Shitara, Y., Itoh, T., Sato, H., Li, A.P. & Sugiyama, Y. Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J. Pharmacol. Exp. Ther. 304, 610-616 (2003).
7. Lam, J.L. & Benet, L.Z. Hepatic microsome studies are insufficient to characterize in vivo hepatic metabolic clearance and metabolic drug-drug interactions: studies of digoxin metabolism in primary rat hepatocytes versus microsomes. Drug Metab. Dispos. 32, 1311-1316 (2004).
8. Sun, H., Huang, Y., Frassetto, L. & Benet, L.Z. Effects of uremic toxins on hepatic uptake and metabolism of erythromycin. Drug Metab. Dispos. 32, 1239-1246 (2004).
9. Lau, Y.Y., Wu, C.Y., Okochi, H. & Benet, L.Z. Ex situ inhibition of hepatic uptake and efflux significantly changes metabolism: hepatic enzyme-transporter interplay. J. Pharmacol. Exp. Ther. 308, 1040-1045 (2004).
10. Lau, Y.Y., Okochi, H., Huang, Y. & Benet, L.Z. Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism. Drug Metab. Dispos. 34, 1175-1181 (2006).
11. Lau, Y.Y., Huang, Y., Frassetto, L. & Benet, L.Z. Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin. Pharmacol. Ther. 81, 194-204 (2007).
12. Lam, J.L., Shugarts, S.B., Okochi, H. & Benet, L.Z. Elucidating the effect of final-day dosing of rifampin in induction studies on hepatic drug disposition and metabolism. J. Pharmacol. Exp. Ther. 319, 864-870 (2006).
13. Feldman, J.M. Glyburide: a second-generation sulfonylurea hypoglycemic agent. History, chemistry, metabolism, pharmacokinetics, clinical use and adverse effects. Pharmacotherapy 5, 43-62 (1985).
14. Niemi, M., Cascorbi, I., Timm, R., Kroemer, H.K., Neuvonen, P.J. & Kivistö, K.T. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. Clin. Pharmacol. Ther. 72, 326-332 (2002).
15. Kirchheiner, J. et al. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clin. Pharmacol. Ther. 71, 286-296 (2002).
16. Surekha, V., Peter, J.V., Jeyaseelan, L. & Cherian, A.M. Drug interaction: rifampicin and glibenclamide. Natl. Med. J. India 10, 11-12 (1997).
17. Self, T.H., Tsiu, S.J. & Fowler, J.W. Jr. Interaction of rifampin and glyburide. Chest 96, 1443-1444 (1989).
18. Niemi, M., Backman, J.T., Neuvonen, M., Neuvonen, P.J. & Kivistö, K.T. Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. Clin. Pharmacol. Ther. 69, 400-406 (2001).
19. Lin, G., Hays, D.P. & Spillane, L. Refractory hypoglycemia from ciprofloxacin and glyburide interaction. J. Toxicol. Clin. Toxicol. 42, 295-297 (2004).
20. Vavricka, S.R., Van Montfoort, J., Ha, H.R., Meier, P.J. & Fattinger, K. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology 36, 164-172 (2002).
21. Baldes, C., Koenig, P., Neumann, D., Lenhof, H.P., Kohlbacher, O. & Lehr, C.M. Development of a fluorescence-based assay for screening of modulators of human organic anion transporter 1B3 (OATP1B3). Eur. J. Pharm. Biopharm. 62, 39-43 (2006).
22. Frassetto, L. et al. Cyclosporine pharmacokinetics and dosing modifications in human immunodeficiency virus-infected liver and kidney transplant recipients. Transplantation 80, 13-17 (2005).
23. Golstein, P.E., Boom, A., van Geffel, J., Jacobs, P., Masereel, B. & Beauwens, R. P-glycoprotein inhibition by glibenclamide and related compounds. Pflugers Arch. 437, 652-660 (1999).
24. Combalbert, J. et al. Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily. Drug Metab. Dispos. 17, 197-207 (1989).
25. Kolars, J.C., Schmiedlin-Ren, P., Schuetz, J.D., Fang, C. & Watkins, P.B. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J. Clin. Invest. 90, 1871-1878 (1992).
26. Schuetz, E.G., Schinkel, A.H., Relling, M.V. & Schuetz, J.D. P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc. Natl. Acad. Sci. USA 93, 4001-4005 (1996).
27. Fromm, M.F. et al. The effect of rifampin treatment on intestinal expression of human MRP transporters. Am. J. Pathol. 157, 1575-1580 (2000).
28. Greiner, B. et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J. Clin. Invest. 104, 147-153 (1999).
29. Niemi, M., Backman, J.T., Fromm, M.F., Neuvonen, P.J. & Kivistö, K.T. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin. Pharmacokinet. 42, 819-850 (2003).
30. Bidstrup, T.B., Stilling, N., Damkier, P., Scharling, B., Thomsen, M.S. & Brosen, K. Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide. Eur. J. Clin. Pharmacol. 60, 109-114 (2004).
31. Tirona, R.G., Leake, B.F., Wolkoff, A.W. & Kim, R.B. Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J. Pharmacol. Exp. Ther. 304, 223-228 (2003).
32. van Giersbergen, P.L.M., Treiber, A., Schneiter, R., Dietrich, H. & Dingemanse, J. Inhibitory and inductive effects of rifampin on the pharmacokinetics of bosentan in healthy subjects. Clin. Pharmacol. Ther. 81, 414-419 (2007).
33. Wu, C.Y. & Benet, L.Z. Disposition of tacrolimus in isolated perfused rat liver: Influence of troleandomycin, cyclosporine and GG918. Drug Metab. Dispos. 31, 1292-1295 (2003).